FDA Panel Unanimously Approves Two New Hep C drugs

merc_hepatitis_c_victrelis_0

 

Amid all the angst regarding the high costs of drug discovery, it is refreshing to see two new drugs for Hepatitis C approved by FDA advisory panels. In the past two days the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) unanimously approved Merck’s investigational medicine VICTRELIS (boceprevir) and Vertex’s telaprevir. (Disclaimer: CDD CEO Barry Bunin has been a Vertex Shareholder since the telepravir phase 2 results were announced).

As a community of scientists, clinicians, executives, regulators, patients, and people, we can take a moment to smile and appreciate the progress.   The prognosis is now brighter for those with Hepatitis C.   And given the strong pipelines, new targets, and large need, it seems that the Hep C combination therapies will only get better in the near future.

 

 

 

 

 


This blog is authored by members of the CDD Vault community. CDD Vault is a hosted drug discovery informatics platform that securely manages both private and external biological and chemical data. It provides core functionality including chemical registration, structure activity relationship, chemical inventory, and electronic lab notebook capabilities!

CDD Vault: Drug Discovery Informatics your whole project team will embrace!

Translated with Google Translate